Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma

Basit Öğe Kaydı
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridKucukarda, Ahmet/0000-0001-7399-2360
dc.authoridSayin, Sezin/0000-0001-7892-5992
dc.authoridGokyer, Ali/0000-0002-1653-6155
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.contributor.authorGokyer, Ali
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorKostek, Osman
dc.contributor.authorGokmen, Ivo
dc.contributor.authorOzcan, Erkan
dc.contributor.authorSayin, Sezin
dc.contributor.authorTastekin, Ebru
dc.date.accessioned2024-06-12T11:07:52Z
dc.date.available2024-06-12T11:07:52Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: To evaluate clinical and demographic characteristics and the results of cytotoxic treatments of KRAS(G12C), KRAS(other), and next-generation sequencing (NGS) panel negative patients. Methods: NGS data of 1264 patients with non-small cell lung cancer were retrospectively evaluated. Among these patients, the mutation distributions of 1081 patients with metastatic lung adenocarcinoma were analyzed. A total of 150 patients with negative NGS panel or mutant KRAS followed up in our clinic were included. Clinical features, overall survival, first-line chemotherapy responses, and progression-free survival of NGS panel negative, KRAS(G12C), and KRAS(other) groups were compared. Results: In 1081 patients who underwent NGS from tumor tissue with the diagnosis of metastatic lung adenocarcinoma, 296 (27%) NGS panel negative and 276 (26%) KRAS mutant patients were detected. Among these patients, 150 patients whose data were available were 71 (47.3%) NGS panel negative, 54 (36%) KRAS(other), and 25 (16.7%) KRAS(G12C). Clinical features, brain metastasis, and first-line chemotherapy response were similar among groups. Bone metastases were detected more often in the NGS panel negative group (p = 0.03). The median follow-up was 8.4 months. Overall, 107 deaths had occurred at the time of analysis. There was no difference in overall survival (p = 0.56) or progression-free survival (p = 0.71) among NGS panel negative, KRAS(other), and KRAS(G12C) patients. Conclusion: There is no difference in overall survival, first-line chemotherapy response, or progression-free survival among patients with NGS panel negative, KRAS(G12C), or KRAS(other) metastatic lung adenocarcinoma. Bone metastases were observed more frequently in the NGS panel negative group.en_US
dc.identifier.doi10.1177/0300891621996448
dc.identifier.endpage146en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue2en_US
dc.identifier.pmid33624577en_US
dc.identifier.scopus2-s2.0-85101649000en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage141en_US
dc.identifier.urihttps://doi.org/10.1177/0300891621996448
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22211
dc.identifier.volume108en_US
dc.identifier.wosWOS:000680249000001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumori Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLung Adenocarcinomaen_US
dc.subjectNext-Generation Sequencingen_US
dc.subjectKRAS Mutationen_US
dc.subjectKRAS(G12C) Mutationen_US
dc.titleComparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu